Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway

Esaxerenone Protects against Diabetic Cardiomyopathy via Inhibition of the Chemokine and PI3K-Akt Signaling Pathway

(1) Background: Diabetic cardiomyopathy (DCM) is a unique form of cardiomyopathy that develops as a consequence of diabetes and significantly contributes to heart failure in patients. Esaxerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated potential in reducing...

Szczegółowa specyfikacja

Opis bibliograficzny
Główni autorzy: Ziyue Li, Huihui Zhang, Weihan Zheng, Zi Yan, Jiaxin Yang, Shiyu Li, Wenhua Huang
Format: Artykuł
Język:English
Wydane: MDPI AG 2023-12-01
Seria:Biomedicines
Hasła przedmiotowe:
diabetic cardiomyopathy
esaxerenone
pharmacological mechanism
therapy
network pharmacology
Dostęp online:https://www.mdpi.com/2227-9059/11/12/3319

Internet

https://www.mdpi.com/2227-9059/11/12/3319

Podobne zapisy